Testicular Germ Cell Tumours

📋 Key Information Summary

📋

Testicular germ cell tumours (GCTs) are the most common solid malignancy in males aged 15–44 years in Australia, with an incidence of approximately 8–9 per 100,000 per year.
GCTs are divided into seminoma (~50%) and non-seminomatous germ cell tumours (NSGCT) (~40%), with mixed forms classified as NSGCT for management purposes.
Tumour markers — AFP, β-hCG and LDH — are essential for diagnosis, staging, risk stratification and treatment response monitoring.
Pure seminoma with normal AFP; if AFP is elevated regardless of histology, the tumour is managed as NSGCT.
Standard primary treatment is inguinal orchidectomy with removal of the entire spermatic cord — trans-scrotal biopsy is contraindicated.
Staging requires CT chest/abdomen/pelvis, serum tumour markers and histopathological review; PET-CT has a role in seminoma residual masses post-chemotherapy.
Stage I seminoma: active surveillance is preferred; adjuvant para-aortic radiotherapy (20 Gy) or single-agent carboplatin AUC 7 × 1 cycle are alternatives.
Stage I NSGCT: risk-stratified — surveillance for low-risk (pT1, no LVI); adjuvant BEP × 1 cycle or nerve-sparing RPLND for high-risk (pT2–4 or LVI present).
Advanced disease (Stage IIC–III): cisplatin-based combination chemotherapy — BEP × 3 cycles (good risk) or BEP × 4 or VIP × 4 (intermediate/poor risk) per IGCCCG classification.
Post-chemotherapy residual masses: resect if teratoma elements or viable cancer suspected; in seminoma, PET-CT at 6 weeks post-chemo guides surgery vs observation.
All GCT patients should be referred to a specialised multidisciplinary team (MDT) and treated at an experienced centre; fertility counselling and sperm cryopreservation should be offered pre-treatment.
Cure rates exceed 95% overall; even disseminated disease is curable in >70–80% of cases with appropriate cisplatin-based therapy.
Cisplatin carries significant toxicity — ototoxicity, peripheral neuropathy, nephrotoxicity, Raynaud phenomenon — requiring baseline audiology and ongoing monitoring.
Aboriginal and Torres Strait Islander men may present later with more advanced disease; culturally safe engagement and improved rural/remote access are essential.

Introduction & Australian Epidemiology

Testicular germ cell tumours (GCTs) are the most common solid malignancy in young men and represent a paradigm of curable cancer, even in the metastatic setting. In Australia, GCTs account for approximately 8–9 new diagnoses per 100,000 males per year, with a peak incidence between 20 and 40 years of age. The Australian Institute of Health and Welfare (AIHW) estimates around 800–900 new cases annually, with a trend of slowly increasing incidence over the past three decades.

GCTs are broadly classified into seminomas and non-seminomatous germ cell tumours (NSGCT), each with distinct biological behaviour, marker profiles and treatment pathways. Approximately 50% are pure seminoma, 40% are NSGCT and 10% are mixed — the latter managed as NSGCT. The majority originate from the testis, with extragonadal GCTs (mediastinal, retroperitoneal, pineal) comprising <5% of cases.

Australia has among the highest incidence rates worldwide, particularly in men of Northern European descent. Known risk factors include cryptorchidism (relative risk 4–8×), family history (6–10× risk with first-degree relative affected), personal history of contralateral GCT (2–3%), testicular dysgenesis syndrome and disorders of sex development.

The curability of GCTs, even in advanced stages, is attributable to exquisite cisplatin sensitivity. Overall five-year survival exceeds 95% for localised disease and 70–80% for disseminated disease classified as poor-risk by the International Germ Cell Cancer Collaborative Group (IGCCCG). Management should occur within a multidisciplinary setting at experienced tertiary centres with access to specialist surgical, medical and radiation oncology services.

This guideline covers the classification, tumour marker evaluation, staging investigations and management strategies for testicular GCTs in the Australian context, aligned with Therapeutic Guidelines, Cancer Council Australia clinical practice guidelines and international consensus (NCCN, ESMO, EAU).

Classification: Seminoma vs NSGCT

Accurate histopathological classification is the cornerstone of GCT management. All testicular GCTs derive from germ cell neoplasia in situ (GCNIS), also known as carcinoma in situ of the testis. The WHO 2022 classification divides GCTs into:

Feature	Seminoma	NSGCT
Frequency	~50% of GCTs	~40% (mixed managed as NSGCT)
Histological subtypes	Classic seminoma (90%); spermatocytic tumour (<5%)	Embryonal carcinoma, yolk sac tumour, choriocarcinoma, teratoma (mature/immature), mixed
Peak age	30–40 years	20–30 years (younger)
AFP	Always normal — if elevated, tumour contains non-seminomatous elements	Elevated in ~50–70%
β-hCG	Mildly elevated in ~15–20%	Elevated in ~40–60%
Growth pattern	Slow, predominantly lymphatic spread	Aggressive; haematogenous and lymphatic spread
Metastatic pattern	Retroperitoneal lymph nodes first	Retroperitoneal nodes + lungs, liver, brain, bone
Radiosensitivity	Highly radiosensitive	Less radiosensitive; chemo-driven
Chemosensitivity	Cisplatin-sensitive	Very cisplatin-sensitive (especially embryonal, chorio)
Teratoma component	Absent	Present in ~40% — chemo-resistant, requires surgical resection

⚠️

AFP rule: Pure seminoma never produces AFP. If AFP is elevated above the institutional upper limit of normal, the tumour must be managed as NSGCT regardless of histopathological findings, as occult non-seminomatous elements are presumed present.

Spermatocytic tumour (formerly spermatocytic seminoma) is a distinct entity with an excellent prognosis, occurring predominantly in men >50 years. It lacks GCNIS, has no association with cryptorchidism and almost never metastasises. Management is orchidectomy alone with surveillance.

Extragonadal Germ Cell Tumours

Extragonadal GCTs arise most commonly in the anterior mediastinum or retroperitoneum and are presumed to originate from midline embryonic migration defects. Mediastinal NSGCTs carry a worse prognosis than gonadal equivalents. Primary mediastinal non-seminomatous GCTs are classified as intermediate-risk by IGCCCG. Klinefelter syndrome (47,XXY) is associated with mediastinal GCTs.

Tumour Markers (AFP, β-hCG & LDH)

Serum tumour markers are essential for GCT diagnosis, classification, staging, treatment response monitoring and post-treatment surveillance. Three markers are routinely measured:

Marker	Produced by	Normal range	Half-life	Clinical significance
AFP (α-fetoprotein)	Yolk sac tumour; embryonal carcinoma	<10 kU/L (varies by lab)	5–7 days	Elevated in ~50–70% of NSGCT. Never elevated in pure seminoma. Critical for distinguishing seminoma from NSGCT.
β-hCG (β-human chorionic gonadotropin)	Syncytiotrophoblast (choriocarcinoma); seminoma (syncytiotrophoblastic giant cells)	<5 IU/L (non-pregnant male)	1–3 days	Elevated in ~15–20% seminomas; ~40–60% NSGCTs. Can cause gynaecomastia via oestrogen cross-reaction.
LDH (lactate dehydrogenase)	Non-specific; reflects tumour bulk and proliferation	<250 U/L (varies by lab)	~1 day	Prognostic marker; included in IGCCCG risk classification. Less specific but correlates with disease burden.

Marker Kinetics & Interpretation

Pre-orchidectomy: Always obtain AFP, β-hCG and LDH before orchidectomy. These levels become the baseline for subsequent monitoring.
Post-orchidectomy half-life kinetics: AFP should normalise within ~25–30 days (4–5 half-lives). β-hCG should normalise within ~8–12 days. Persistently elevated or rising markers post-orchidectomy indicate metastatic disease.
During chemotherapy: Marker decline rate is prognostic. Failure of markers to decline by ≥10% per cycle suggests chemoresistance and may warrant escalation.
Discordant markers: AFP rise with falling β-hCG (or vice versa) should be treated as disease progression — management follows the rising marker.
Non-malignant causes of β-hCG elevation: Hypogonadism, marijuana use, liver disease and cross-reacting LH. Ensure specimens are tested with an appropriate assay.
Tissue marker of note: SALL4 is a sensitive immunohistochemical marker for GCNIS-derived GCTs; OCT3/4 (POU5F1) is positive in seminoma and embryonal carcinoma.

ℹ️

MBS note: AFP, β-hCG and LDH are Medicare Benefits Schedule (MBS)-listed items when requested in the context of testicular malignancy (MBS items 66528, 66529, 66515). Ensure clinical indication is clearly documented to avoid billing rejection.

Staging & Investigations

Staging of testicular GCTs integrates clinical examination, serum tumour markers, histopathology and cross-sectional imaging. The TNM 8th edition (UICC/AJCC) and the IGCCCG prognostic classification are both used.

Initial Workup

Essential

Scrotal ultrasound

First-line imaging to confirm an intratesticular mass. Hypoechoic, vascular lesion is characteristic. MBS item 55800.

Essential

Inguinal orchidectomy

Definitive tissue diagnosis. Trans-scrotal biopsy is contraindicated (risk of tumour seeding along scrotal lymphatics).

Essential

Serum AFP, β-hCG, LDH

Pre-orchidectomy and serial monitoring. Critical for classification and IGCCCG risk grouping.

Essential

CT chest, abdomen & pelvis with IV contrast

Detects retroperitoneal lymphadenopathy (most common metastatic site) and visceral/pleural metastases. CT chest is mandatory even for apparent Stage I disease.

Available

PET-CT (¹⁸F-FDG)

Role: post-chemotherapy residual mass evaluation in seminoma (at ≥6 weeks post-chemotherapy). Not routinely indicated for initial staging. PET-negative residual seminoma can be observed.

Referral

MRI brain

Indicated if brain metastases suspected (symptoms such as headache, neurological deficit) or in choriocarcinoma/NSGCT with high β-hCG (>5,000 IU/L) where brain metastases are more common.

Available

Contralateral testis ultrasound

Screen for GCNIS or synchronous tumour, especially if risk factors present (cryptorchidism, atrophic testis, infertility).

Available

Sperm cryopreservation

Offer to all patients before orchidectomy or chemotherapy. Fertility may already be impaired in ~50% of GCT patients at diagnosis. Storage available at public and private fertility clinics Australia-wide.

TNM 8th Edition — Simplified Stage Groups

Stage	Definition	Seminoma	NSGCT
I	Confined to testis; no metastases	~75% at presentation	~65% at presentation
IA	pT1, no LVI, markers declining	Lower risk	Lower risk (surveillance candidate)
IB	pT2–4 and/or LVI present	Higher risk	Higher risk (adjuvant chemo consideration)
IS	Any T, markers persistently elevated post-orchidectomy	Treated as metastatic	Treated as metastatic
II	Retroperitoneal lymph node metastases	IIA ≤2 cm; IIB 2–5 cm; IIC >5 cm	Same size criteria
III	Supradiaphragmatic or visceral metastases	III (non-pulmonary visceral = IIIC)	Same; non-pulmonary visceral = poor risk

IGCCCG Prognostic Classification (Metastatic Disease)

Risk group	Seminoma	NSGCT	5-yr PFS	5-yr survival
Good	Any primary site; non-pulmonary visceral mets absent; AFP normal; any β-hCG or LDH	Testis/retroperitoneal primary; no non-pulmonary visceral mets; AFP <1,000 ng/mL; β-hCG <5,000 IU/L; LDH <10× ULN	82%	86%
Intermediate	Non-pulmonary visceral metastases present (liver, bone, brain)	Testis/retroperitoneal primary; no non-pulmonary visceral mets; AFP 1,000–10,000 ng/mL OR β-hCG 5,000–50,000 IU/L OR LDH 10–100× ULN	67%	72%
Poor	N/A (seminoma has no poor-risk group)	Mediastinal primary OR non-pulmonary visceral mets OR AFP >10,000 ng/mL OR β-hCG >50,000 IU/L OR LDH >100× ULN	41%	48%

⚠️

Stage IS: Persistently elevated or rising tumour markers after orchidectomy (with normal imaging) defines Stage IS. These patients must be treated as having metastatic disease — surveillance is contraindicated.

Management: Orchidectomy, Chemotherapy & Radiotherapy

Management of testicular GCTs is stage- and histology-dependent. The multidisciplinary team (MDT) — comprising urological oncologist, medical oncologist, radiation oncologist, pathologist and specialist nurse — should guide all treatment decisions at an experienced centre.

A. Primary Inguinal Orchidectomy

Inguinal orchidectomy with high ligation of the spermatic cord at the internal ring is the standard primary procedure for all suspected testicular GCTs. It provides definitive histopathological diagnosis and is curative in most Stage I cases.

🚨

Never perform trans-scrotal biopsy or orchiopexy through a scrotal incision. Scrotal violation disrupts the anatomical lymphatic drainage of the testis and may convert a predictable inguinal/retroperitoneal nodal pathway to unpredictable inguinal, pelvic and retroperitoneal spread, complicating subsequent management.

Testis-Sparing Surgery (TSS)

TSS (partial orchidectomy) is an option only in specific circumstances: small tumour (<2 cm) in a solitary testis, synchronous bilateral GCTs, or patient preference after thorough counselling. Requires intraoperative frozen section, contralateral biopsy to exclude GCNIS and postoperative surveillance. Not standard practice.

B. Management of Stage I Disease

Stage I Seminoma

Option 1 (Preferred)

Active Surveillance

Relapse rate ~15–20%, almost always salvageable with radiotherapy or chemotherapy. Avoids treatment toxicity in ~80–85% of patients.

Schedule: CT abdomen/pelvis + markers every 4–6 months × 2 years, then 6–12 monthly × 3 years, then annually to 10 years. Chest X-ray as per protocol.

Option 2

Adjuvant Para-aortic Radiotherapy

20 Gy in 10 fractions to the para-aortic strip. Relapse rate <1–2%. Acute toxicity (nausea, fatigue) is generally mild.

Oncology centre. Long-term risk: secondary malignancy (~2% at 20 years), infertility (shielded ipsilateral iliac nodes to preserve fertility).

Option 3

Adjuvant Carboplatin × 1 Cycle

Carboplatin AUC 7 IV, single dose. Relapse rate ~4–5%. Less acute toxicity than radiotherapy.

Outpatient infusion. PBS Restricted Benefit for testicular seminoma. Risk of late effects (secondary malignancy) probably lower than RT but long-term data pending.

💊

Carboplatin

Paraplatin® · Platinum agent · Cytotoxic

Adult dose (adjuvant) AUC 7 (Calvert formula) IV, single dose, Day 1. Cycle repeats only if high-risk Stage I.

Adjuvant × 2 cycles (high risk) Carboplatin AUC 7 IV Day 1, every 21 days × 2 cycles — alternative for patients declining surveillance and RT

Paediatric dose Not applicable (pre-pubertal testicular GCTs are extremely rare and managed differently)

Renal adjustment Dose based on GFR via Calvert formula — inherently adjusted. Avoid if GFR <30 mL/min unless specialist decision

Hepatic adjustment No specific adjustment; use with caution in severe hepatic impairment

PBS status ✔ PBS General Benefit

Stage I NSGCT

Risk stratification is based on pathology: low risk (pT1, no lymphovascular invasion [LVI]) vs high risk (pT2–4 and/or LVI present).

1

Low-risk Stage I (pT1, no LVI)

Active surveillance is preferred. Relapse rate ~15–20%; 99% salvageable with chemotherapy. Avoids unnecessary treatment in ~80%.

2

High-risk Stage I (pT2–4 or LVI)

Options: Surveillance (relapse rate ~50%); adjuvant BEP × 1 cycle (relapse rate ~1–3%); or nerve-sparing RPLND (relapse rate ~10% with pathologist-confirmed nodes).

3

Decision-making

Patient preference, compliance with surveillance, access to experienced surgical centre, fertility considerations and psychological factors all influence the choice.

C. Chemotherapy for Advanced GCTs

Cisplatin-based combination chemotherapy is the backbone of treatment for metastatic GCT. The BEP regimen (bleomycin, etoposide, cisplatin) is standard first-line therapy. The number of cycles and regimen choice depend on IGCCCG risk group and histology.

IGCCCG Risk	Regimen	Cycles	Notes
Good risk	BEP	3 cycles	Standard of care. EP (etoposide/cisplatin) × 4 cycles is an acceptable alternative if bleomycin contraindicated (age >50, renal impairment, smoking, lung disease).
Intermediate / Poor risk	BEP × 4 or VIP × 4	4 cycles	VIP (etoposide, ifosfamide, cisplatin) used if bleomycin contraindicated or pulmonary toxicity risk too high.

BEP Regimen — Detailed

💊

Bleomycin

Bleomycin · Glycopeptide antibiotic · Cytotoxic

Adult dose 30,000 IU (30 units) IV/IM, Days 1, 8 and 15 of each 21-day cycle

Key toxicity Pulmonary fibrosis (cumulative dose-related, ~10% at >300 units). Monitor FVC/TLCO before each dose. Fever/rigors common after first dose (pre-medicate with paracetamol).

Renal adjustment Dose reduce if CrCl <50 mL/min — withhold if <30 mL/min

Age limit Avoid in patients >50 years due to increased pulmonary toxicity risk; use VIP instead

PBS status ✔ PBS General Benefit

💊

Etoposide

Vepesid® · Topoisomerase II inhibitor · Cytotoxic

Adult dose (BEP) 100 mg/m² IV daily × 5 days per cycle (Days 1–5 of each 21-day cycle)

Key toxicity Myelosuppression, alopecia, secondary AML (rare, ~0.5% lifetime risk)

Renal adjustment Reduce dose if CrCl <50 mL/min

PBS status ✔ PBS General Benefit

💊

Cisplatin

Cisplatin · Platinum agent · Cytotoxic

Adult dose (BEP) 20 mg/m² IV daily × 5 days per cycle (Days 1–5 of each 21-day cycle) OR 100 mg/m² IV Day 1 per cycle (both equivalent)

Key toxicity Nephrotoxicity (aggressive IV hydration required: ≥2 L pre/post cisplatin), ototoxicity (high-frequency hearing loss, ~20–30%), peripheral neuropathy, severe nausea/vomiting (highly emetogenic — aprepitant + 5-HT3 antagonist + dexamethasone)

Renal adjustment Contraindicated if CrCl <60 mL/min unless dose-modified; monitor serum creatinine and electrolytes each cycle

Pre-treatment requirements Baseline audiometry, GFR (CrCl or nuclear GFR), serum Mg²⁺, K⁺, Ca²⁺. Reassess each cycle.

PBS status ✔ PBS General Benefit

💊

Ifosfamide

Holoxan® · Alkylating agent · Cytotoxic

Adult dose (VIP) 1,200 mg/m² IV daily × 5 days per cycle (Days 1–5), with mesna uroprotection (400 mg/m² IV TDS on days 1–5)

Key toxicity Haemorrhagic cystitis (mitigated by mesna), CNS toxicity (encephalopathy, especially at high dose or renal impairment), myelosuppression

Renal adjustment Dose reduce if CrCl <60 mL/min; increased encephalopathy risk in renal impairment

PBS status ✔ PBS General Benefit

🚨

Bleomycin pulmonary toxicity: Monitor pulmonary function (FVC and/or TLCO) before each bleomycin dose. If FVC declines >10–15% or symptomatic dyspnoea develops, discontinue bleomycin and substitute with VIP or EP. Supplemental oxygen during general anaesthesia in former bleomycin patients should be minimised (use lowest FiO₂ necessary) — risk of fatal ARDS-like syndrome persists lifelong.

D. Radiotherapy

Radiotherapy remains an important treatment modality primarily for seminoma:

Stage I seminoma adjuvant: Para-aortic field, 20 Gy / 10 fractions over 2 weeks. Involves a single anterior-posterior field from T11/L1 to L5/S1. Modern techniques (3D-CRT or IMRT) minimise dose to kidneys and bowel.
Stage IIA/IIB seminoma: Primary radiotherapy (30 Gy to para-aortic + ipsilateral iliac nodes, with boost to 36 Gy if Stage IIB) is a standard first-line option. Chemotherapy (BEP × 3 or EP × 4) is preferred for Stage IIB with bulkier disease (>3 cm nodes).
Radiotherapy is not used for NSGCT — cisplatin-based chemotherapy is the standard for all metastatic NSGCT.
Palliative radiotherapy: Effective for symptomatic bone, brain or soft tissue metastases from either seminoma or NSGCT.

E. Post-Chemotherapy Residual Mass Management

Residual masses after chemotherapy are common (~30–40% of patients) and management depends on histology:

Post-chemo residual mass in NSGCT: Surgical resection (post-chemotherapy RPLND) is recommended if mass >1 cm. Pathology shows: necrosis/fibrosis (40–50%), teratoma (40%), or viable GCT (10–15%). Viable cancer requires further chemotherapy.
Post-chemo residual mass in seminoma: PET-CT performed ≥6 weeks (ideally 8–12 weeks) after chemotherapy. PET-negative: observe (malignancy risk <10%). PET-positive: biopsy or surgical resection if feasible; further chemo or RT if positive histology.
Growing teratoma syndrome: Teratoma may enlarge during or after chemotherapy (chemo-resistant, but benign histology). Surgical resection is the only effective treatment.
Late relapse (>2 years): Often teratoma. Chemotherapy has limited efficacy; surgical resection is preferred.

F. Salvage Chemotherapy

Patients who relapse after first-line chemotherapy may be salvaged with second-line regimens:

Conventional-dose salvage: TIP (paclitaxel, ifosfamide, cisplatin) × 4 cycles — standard second-line option.
High-dose chemotherapy (HDCT): Carboplatin + etoposide with autologous stem cell transplant (ASCT). Reserved for cisplatin-refractory disease or third-line therapy. Available at major centres (Peter MacCallum, Chris O'Brien Lifehouse, Royal Adelaide).
Gemcitabine + oxaliplatin (GEMOX) or gemcitabine + paclitaxel are options for further-line therapy.
Prognostic factors at salvage: platinum-free interval >2 years, CR to first-line, low post-relapse markers — predict better salvage outcomes.

Special Populations

👶 Paediatric Considerations

Pre-pubertal testicular yolk sac tumour: Most common in children <2 years. Orchidectomy alone is curative in Stage I. Surveillance is standard. Chemotherapy (cisplatin-based) used for metastatic disease. BEP regimen dose-adjusted for body surface area.

Adolescents (13–18 years): Managed as per adult protocols. Fertility preservation (sperm banking) should be discussed post-puberty. Testicular prosthesis available and well-accepted in this age group.

🤰 Fertility & Pregnancy

Pre-treatment: ~50% of GCT patients have impaired spermatogenesis at diagnosis. Offer sperm cryopreservation to all patients before orchidectomy or chemotherapy. Medicare-rebated at public fertility centres.

Post-treatment: Spermatogenesis recovers in ~80% within 2–5 years after BEP chemotherapy. Higher cumulative doses (4 cycles BEP or VIP) delay recovery. Radiation to testes causes temporary azoospermia (recovery in 18–24 months with <1 Gy scatter dose).

Offspring risk: No increased teratogenicity or congenital abnormality rates in children conceived after GCT treatment (after full recovery period).

👴 Elderly (>50 years)

Bleomycin avoidance: Pulmonary toxicity risk increases significantly >50 years. Substitute VIP for BEP or use EP × 4 for good-risk disease.

Cisplatin: Increased risk of nephrotoxicity and peripheral neuropathy. Ensure adequate hydration, consider GFR-based dose adjustment, and monitor closely.

🫘 Renal Impairment

Cisplatin: Contraindicated if CrCl <60 mL/min (unless specialist). Aggressive IV hydration mandatory (≥2 L pre-cisplatin, post-cisplatin).

Carboplatin: Can substitute for cisplatin in renal impairment (Calvert formula inherently adjusts), but response rates are slightly lower for advanced GCT — specialist input required.

Bleomycin: Reduce dose or withhold if CrCl <30 mL/min.

🫁 Hepatic Impairment

Etoposide: Metabolised hepatically; dose reduce in severe impairment (bilirubin >51 µmol/L — reduce dose by 50%).

Bleomycin and cisplatin: Primarily renally cleared — no major hepatic adjustment, but use with caution in severe liver disease due to altered protein binding and coagulopathy risk.

🛡️ Immunocompromised

HIV: GCT incidence is increased in HIV-positive men (particularly seminoma). Management should be in collaboration with an infectious disease specialist. Standard chemotherapy regimens can be used with careful monitoring of CD4 count, opportunistic infection prophylaxis and antiretroviral drug interactions (particularly azidothymidine and etoposide).

Post-transplant: No specific GCT association, but immunosuppressive drug interactions must be considered.

Monitoring & Surveillance

Long-term surveillance is essential for all GCT patients regardless of stage, given the potential for late relapse and treatment-related sequelae.

Surveillance Schedule — Stage I (Post-Orchidectomy)

Year 1

Markers (AFP, β-hCG, LDH) + CT abdomen/pelvis every 3 months. Chest X-ray every 3–6 months. Clinical examination each visit.

Year 2

Markers + CT every 3–4 months. Chest X-ray every 6 months.

Years 3–5

Markers + CT every 6 months. Chest X-ray annually.

Years 5–10

Markers annually. CT annually (seminoma) or as clinically indicated (NSGCT). Chest X-ray annually.

>10 years

Annual clinical review. Low risk of late relapse for seminoma. NSGCT: late relapse possible (teratoma) — maintain awareness.

Long-Term Toxicity Monitoring (Post-Chemotherapy)

Toxicity	Agent	Monitoring
Pulmonary fibrosis	Bleomycin	Spirometry (FVC) and DLCO annually for 2 years; earlier if symptomatic. Lifetime caution with supplemental O₂ in anaesthesia.
Ototoxicity	Cisplatin	Audiometry at baseline and annually for 2–5 years. High-frequency hearing loss may progress after treatment cessation.
Peripheral neuropathy	Cisplatin	Neurological examination; NCS if symptomatic. Symptoms may worsen for 3–6 months post-chemotherapy (coasting effect).
Raynaud phenomenon	Bleomycin ± cisplatin	Clinical assessment. Reported in ~20–40% of patients. Avoid cold exposure. Nifedipine may be trialled for symptoms.
Secondary malignancy	Radiotherapy; etoposide; cisplatin	Increased risk of solid tumours in RT field (stomach, colon, pancreas) at 10–20 years. Secondary AML/MDS rare (~0.5%) after etoposide. Lifelong cancer screening.
Cardiovascular	Cisplatin	Increased risk of coronary artery disease, hypertension, hyperlipidaemia, metabolic syndrome. Annual cardiovascular risk assessment post-cisplatin.
Hypogonadism	Orchidectomy ± chemo	Check testosterone levels if symptoms (fatigue, low libido, erectile dysfunction). Contralateral testicular function may be impaired.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Epidemiology & burden

AIHW data suggest lower incidence of testicular GCT in Aboriginal and Torres Strait Islander men compared with non-Indigenous Australians, but stage at presentation may be later and outcomes potentially poorer due to access barriers. Cancer survival disparities for Aboriginal and Torres Strait Islander peoples are well documented across multiple tumour types.

Access to specialist services

Specialist urology, medical oncology and radiation oncology services are concentrated in major metropolitan centres. Aboriginal and Torres Strait Islander men from remote and very remote communities face significant travel burdens, financial costs and cultural disconnection to access treatment. Telehealth consultations (MBS-rebated) should be utilised where possible for MDT discussion, surveillance and supportive care.

Cultural safety

Testicular examination and discussion of genital health requires culturally sensitive communication. Engage Aboriginal Health Workers and Liaison Officers (AHWLOs) in all consultations. Respect kinship obligations and gender-specific cultural protocols. Provide information in plain language and culturally appropriate formats.

Fertility & psychosocial

Fertility preservation may be less accessible in remote settings. Sperm cryopreservation requires travel to regional or metropolitan centres. Psychosocial support, including connection to Aboriginal Community Controlled Health Organisations (ACCHOs), should be integral to care planning.

Comorbidities

Higher baseline rates of chronic kidney disease, cardiovascular disease and diabetes in Aboriginal and Torres Strait Islander populations may impact cisplatin tolerance and treatment toxicity. Pre-treatment assessment should include GFR estimation (CKD-EPI preferred) and comorbidity review.

Recommended actions

1) Prioritise patient-initiated follow-up via ACCHOs with shared-care protocols.
2) Ensure all Aboriginal and Torres Strait Islander patients are offered navigation support.
3) Utilise the Patient-Assisted Travel Scheme (PATS) and state-based equivalents for treatment-related travel.
4) Advocate for remote-area chemotherapy delivery capability for consolidation cycles where safe.

📚 References

1. International Germ Cell Cancer Collaborative Group (IGCCCG). International consensus on the classification and treatment of germ cell cancer. Ann Oncol. 1997;8(4):329–339.
2. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs — Part A: renal, penile and testicular tumours. Eur Urol. 2016;70(1):93–105.
3. Cancer Council Australia Testicular Cancer Guidelines Working Party. Clinical practice guidelines for the management of testicular cancer. Sydney: Cancer Council Australia. Available from: https://wiki.cancer.org.au/australiawiki/index.php?oldid=168597.
4. Beyer J, Albers P, Altena R, et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol. 2013;24(4):878–888.
5. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Testicular Cancer, Version 2.2024. Available from: https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf.
6. Honecker F, Aparicio J, Berney D, et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol. 2018;29(8):1658–1686.
7. Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol. 1989;7(3):387–391.
8. Albers P, Albrecht W, Algaba F, et al. Guidelines on testicular cancer. Eur Urol. 2022;82(2):149–166.
9. Australian Institute of Health and Welfare (AIHW). Cancer in Australia 2023. Cancer Series no. 139. Cat. no. CAN 144. Canberra: AIHW; 2023.
10. Oldenburg J, Fosså SD, Nuver J, et al. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi125–vi132.
11. Fung C, Dinh P, Ardeshir-Rouhani-Fard S, Schaffer K, Fossa SD, Travis LB. Toxicities associated with cisplatin-based chemotherapy and radiotherapy in long-term testicular cancer survivors. Urol Oncol. 2018;36(4):156–166.
12. Australian Government Department of Health. Pharmaceutical Benefits Scheme — Cisplatin, Carboplatin, Bleomycin, Etoposide, Ifosfamide. Available from: https://www.pbs.gov.au.
13. Aboriginal and Torres Strait Islander Health Performance Framework 2023 — Cancer. Australian Institute of Health and Welfare. Available from: https://www.pc.gov.au/ongoing/closing-the-gap.
14. Feldman DR, Motzer RJ. Good-risk disseminated germ cell tumors: recent progress and future directions. Semin Oncol. 2019;46(3):165–177.